# Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

> **NCT05622994** · PHASE2 · UNKNOWN · sponsor: **Hospital Nacional de Parapléjicos de Toledo** · enrollment: 80 (estimated)

## Conditions studied

- Spinal Cord Injuries

## Interventions

- **DRUG:** Rimonabant

## Key facts

- **NCT ID:** NCT05622994
- **Lead sponsor:** Hospital Nacional de Parapléjicos de Toledo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11
- **Primary completion:** 2023-11
- **Final completion:** 2023-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622994, "Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05622994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*